Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 11, 2026

Zentalis Pharmaceuticals, Inc. (ZNTL)

A forensic read on Zentalis Pharmaceuticals, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-9.0

Distress distance

Forensic signals

-49.5%

ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Zentalis Pharmaceuticals, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -9.0, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by shareholder returns.

What the filings flag

FCF ($125M)

FY2025

Shareholder returns. Returned $10M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($125M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.

+4.8%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +10% over the last 2 years to FY2025 (+4.8%/yr). The count is growing — 65.4M shares in FY2023, 71.9M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~4.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~9%.

$4M

FY2024

Goodwill impairments. Took $4M of goodwill writedowns across 1 year (FY2024 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Free Cash Flow-$125.2M

Return on Equity-49.5%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Zentalis Pharmaceuticals, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 11, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.